Title
Category
Credits
Event date
Cost
  • Oncology
  • ANCC
  • Participation
$0.00
Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
04/21/2021
$0.00
This educational initiative is targeted to pediatric hematologists/oncologists, general hematologists/oncologists, hematologists, oncology researchers, and hem/onc fellows attending the 2021 American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting, as well as other members of the multidisciplinary hematology/oncology NF1 care team.
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
04/23/2021
$0.00
This Grand Rounds series is targeted to physician specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants who manage patients with ESRD.Supported through an independent educational grant from AstraZeneca.
  • Oncology
  • ANCC
  • Participation
04/27/2021
$0.00
First 100 registrants receive a $20 Food and Beverage credit (provided by ONS)!
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
04/29/2021
$0.00
This series will review the role of the B-cell receptor pathway in the treatment of B-cell malignancies and explore the latest safety and efficacy data for novel, oral agents such as BTK inhibitors, PI3K inhibitors, and BCL-2 inhibitors.Presented by Creative Educational Concepts, Inc. and accredited by the University of Cincinnati.Supported through independent educational grants from AstraZeneca and Janssen.
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
04/29/2021
$0.00
This Grand Rounds series is targeted to physician specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants who manage patients with ESRD.Supported through an independent educational grant from AstraZeneca.
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
05/14/2021
$0.00
This Grand Rounds series is targeted to physician specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants who manage patients with ESRD.Supported through an independent educational grant from AstraZeneca.
  • Oncology
  • ANCC
  • Participation
05/20/2021
$0.00
Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
05/21/2021
$0.00
This Grand Rounds series is targeted to physician specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants who manage patients with ESRD.Supported through an independent educational grant from AstraZeneca.
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
05/22/2021
$0.00
This series will review the role of the B-cell receptor pathway in the treatment of B-cell malignancies and explore the latest safety and efficacy data for novel, oral agents such as BTK inhibitors, PI3K inhibitors, and BCL-2 inhibitors.Presented by Creative Educational Concepts, Inc. and accredited by the University of Cincinnati.Supported through independent educational grants from AstraZeneca and Janssen.

Pages